文献速递头颈部肿瘤放疗姑息放疗与转移瘤

头颈部原发灶不明癌不常规行全黏膜照射的结局相当

Comparable Outcomes Without Routine Pan-mucosal Irradiation in Head and Neck Carcinoma of Unknown Primary.
PubMed 文献 · Adv Radiat Oncol · 2026-07-03

该回顾性双中心分析纳入134例经充分分期的头颈部原发灶不明癌患者,比较颈部淋巴结照射联合或不联合50 Gy全黏膜照射的结局。全黏膜照射未改善生存或降低黏膜复发,常规应用可能不必要。

要点

  • 黏膜复发均见于持续吸烟者且发生于诊断36个月后。

核心结论

  • 在经充分分期的头颈部原发灶不明癌中,在标准淋巴结照射基础上加全黏膜照射与生存改善或黏膜复发率降低无关。
  • 黏膜事件出现较晚且仅见于持续吸烟者,提示为第二原发肿瘤而非遗漏的原发灶。
  • 考虑到潜在毒性和生活质量权衡,常规全黏膜照射可能不必要,治疗应个体化。

研究设计与样本

  • 回顾性双中心分析,中心1为2009-2018年,中心2为2005-2023年。
  • 所有患者接受颈淋巴结清扫联合淋巴引流区辅助照射或根治性放化疗;中心2额外接受50 Gy全黏膜照射至上呼吸消化道。
  • 晚期淋巴结病变采用根治性放疗/放化疗。
  • 筛查164例,纳入134例(中心1 n=88,中心2 n=46)。
  • 中位随访72个月(95% CI,48-96)。

关键数值与推荐

  • 全黏膜照射剂量为50 Gy,照射上呼吸消化道。
  • 中位随访72个月(95% CI,48-96)。

临床怎么用

  • 对经充分分期的头颈部原发灶不明癌,可不常规行全黏膜照射。
  • 治疗决策应个体化,权衡潜在毒性与生活质量。
  • 持续吸烟者需关注晚期黏膜事件,可能为第二原发肿瘤。

局限性

  • 回顾性双中心设计,存在选择偏倚可能。
  • 两中心治疗年代范围不同(2009-2018 vs 2005-2023)。
  • 样本量有限(134例),黏膜复发事件数少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evaluate whether adding pan-mucosal irradiation (50 Gy) reduces recurrence or improves survival in head and neck carcinoma of unknown primary. METHODS AND MATERIALS: Retrospective 2-center analysis (center 1, 2009-2018, and center 2, 2005-2023). All patients underwent neck dissection with adjuvant irradiation to lymphatic drainage or definitive radiochemotherapy; center 2 additionally received 50 Gy pan-mucosal irradiation to the upper aerodigestive tract. Definitive radiation therapy/chemoradiation therapy was used for advanced nodal disease. RESULTS: Of 164 screened, 134 were included (center 1, n = 88, and center 2, n = 46). Median follow-up was 72 months (95% CI, 48-96). Sixty-five patients (42%) died (37 vs 28). Overall survival did not differ between centers (log-rank P = .899). Combining centers 1 and 2, there were 39 recurrences in 134 patients; 24 out of 88 patients (27.3%) in center 1 and 15 out of 46 patients in center 2 (32.6%), P = .519. There were no differences noted in time-to-event analysis (log-rank P = .724). Mucosal recurrences occurred in 13 patients (9 vs 4; P = .282); all arose more than 36 months after diagnosis and exclusively in persistent smokers. CONCLUSION: In thoroughly staged head and neck carcinoma of unknown primary, adding pan-mucosal irradiation to standard nodal irradiation was not associated with improved survival or lower mucosal recurrence rates compared with nodal-only fields. The late occurrence of mucosal events and their association with persistent smoking suggest second primary tumors rather than missed index lesions. Given potential toxicity and quality-of-life trade-offs, routine pan-mucosal irradiation may not be warranted, and treatment should be individualized.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Allaf M, Diederich L, Buchali A, et al. Comparable Outcomes Without Routine Pan-mucosal Irradiation in Head and Neck Carcinoma of Unknown Primary. Adv Radiat Oncol. 2026. PMID: 42662753. doi:10.1016/j.adro.2026.102130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。